Perceived Effectiveness of the Vaginal Moisturizer Investigational Product Under Normal Conditions of Use.

NCT06353945 | Completed

• 1 other identifier: HB062-24
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

The present research project aims to evaluate the perceived effectiveness of the product under investigation under normal conditions of use for 28 days, to defend the claims "High hydration power, relief of discomfort and improvement of vaginal tone."

Conditions

Vaginal Atrophy

Outcome Measures

Primary Outcomes (1)

• evaluate the perceived effectiveness of the investigational product

  The perceived efficacy of the subjective method will be evaluated by means of questionnaires answered by the research participants after the first use and 28 days of use of the investigational product using a rating scale. The results of this evaluation will be used to analyze the frequency of scores for each attribute evaluated. Based on the results of the evaluation of the product's efficacy, an analysis of the frequency of scores for each question evaluated.

  28 days

Study Arms (1)

vaginal moisturizer

EXPERIMENTAL

45 participants treated with vaginal moisturizer

Device: vaginal moisturizer

Interventions

vaginal moisturizer DEVICE

vaginal moisturizer

vaginal moisturizer

Eligibility Criteria

• Age: 25 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age range between 25 and 70 years old.
• Phototypes: I to IV, according to Fitzpatrick classification;
• Sex: female
• Intact skin in the evaluation region.
• Participants complaining of vaginal dryness;
• Agree to adhere to the study procedures and requirements: study time, return(s) to the laboratory to perform study procedures, home use of the investigational product, filling out the usage diary, not changing cosmetic habits during the study period .
• Agree not to carry out dermatological or aesthetic treatments until the end of the study and agree not to use any products from the same category as the investigational product.
• Signing of the Free and Informed Consent Form (TCLE).

You may not qualify if:

• Pregnant or breastfeeding women.
• Skin marks in the experimental area that interfere with the assessment of possible skin reactions.
• Active dermatoses (local or disseminated) that could interfere with the study results.
• History of ineffectiveness, allergic reactions, irritation or intense sensation of discomfort to topical products: health products or medications.
• Expected vaccination during the study or up to 3 weeks before the study;
• Not taking vitamin A (acid and/or its derivatives orally or topically up to 1 month before the start of the study.)
• Patients with immunodeficiencies.
• History of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.).
• Use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study (or considering depot corticosteroids, the interval should be 1 month before the selection).
• Aesthetic or dermatological treatment up to 4 weeks before the study.
• Hormonal treatments not stable in the last 3 months.
• Hyperpigmentation associated with the use of drugs such as tetracyclines, phenothiazides or amiodarone.
• Hyperpigmentation associated with photosensitivity.
• People directly involved in carrying out this study and their families.
• History of lack of adherence or unwillingness to adhere to the study protocol.

Sponsors & Collaborators

• Herbarium Laboratorio Botanico Ltda: lead

Study Sites (1)

Kosmoscience Ciência e Tecnologia Cosmética Ltda

Campinas, São Paulo, 13041-315, Brazil

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 28, 2024
• First Posted: April 9, 2024
• Study Start: June 10, 2024
• Primary Completion: July 10, 2024
• Study Completion: July 18, 2024
• Last Updated: November 18, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)